» Articles » PMID: 21947984

The Diagnostic and Prognostic Value of First Hour Glycogen Phosphorylase Isoenzyme BB Level in Acute Coronary Syndrome

Overview
Journal Cardiol J
Date 2011 Sep 28
PMID 21947984
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Evaluating patients with symptoms suggestive of acute coronary syndrome (ACS) is a time consuming, expensive and problematic process in the emergency department. This study aimed to evaluate the diagnostic and prognostic value of glycogen phosphorylase isoenzyme-BB (GP-BB) in ACS.

Methods: A total of 72 patients (mean age 61.8 ± 11.6 years) with ACS were enrolled. The ELISA method for determining GP-BB level was performed and considered positive at 〉 10 ng/mL. Duration of angina, type of ACS, demographic features, myoglobin, creatinine kinase and troponin T (cTnT) were also assessed. The cTnT levels eight hours after pain onset was considered the gold standard test for the diagnosis of myocardial infarction.

Results: The most sensitive biomarker at first hour of admission was GP-BB (95.8%). However, the specificity of GP-BB was low (43.7%). Receiver operating characteristics curve analysis of the GP-BB level for predicting myocardial infarction revealed the area under the curve value as 0.82 (SE 0.04; 95% CI 0.78-0.85). Positive treadmill exercise test (60% vs 17%, p = 0.047), coronary artery disease (CAD; 59% vs 19%, p = 0.007), percutaneous coronary intervention (44% vs 27%, p = 0.031) and 30-day mortality and/or readmission (33% vs 5%, p = 0.028) were found to be higher in unstable angina (UA) patients having GP-BB (+).

Conclusions: GP-BB is considerably cardiosensitive at the first hour of admission in patients with ACS, but the specificity of GP-BB is lower and it is elevated in nearly half of the patients with UA. However, in this group, GP-BB predicts significant CAD and the combined end-point of mortality and re-hospitalization.

Citing Articles

Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A systematic review and meta-analysis.

Ghimire A, Giri S, Khanal N, Rayamajhi S, Thapa A, Bist A J Clin Lab Anal. 2022; 36(5):e24368.

PMID: 35325479 PMC: 9102511. DOI: 10.1002/jcla.24368.


Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients.

Szarpak L, Lapinski M, Gasecka A, Pruc M, Drela W, Koda M J Cardiovasc Dev Dis. 2022; 9(1).

PMID: 35050216 PMC: 8780262. DOI: 10.3390/jcdd9010006.


Glycogen Phosphorylase Isoenzyme Bb, Myoglobin and BNP in ANT-Induced Cardiotoxicity.

Di J, Zhang Z, Xin S Open Life Sci. 2021; 13:561-568.

PMID: 33817127 PMC: 7874740. DOI: 10.1515/biol-2018-0067.


Blood Biomarkers for Stroke Diagnosis and Management.

Kamtchum-Tatuene J, Jickling G Neuromolecular Med. 2019; 21(4):344-368.

PMID: 30830566 PMC: 6722038. DOI: 10.1007/s12017-019-08530-0.


Glycogen Phosphorylase BB: A more Sensitive and Specific Marker than Other Cardiac Markers for Early Diagnosis of Acute Myocardial Infarction.

Singh N, Rathore V, Mahat R, Rastogi P Indian J Clin Biochem. 2018; 33(3):356-360.

PMID: 30072837 PMC: 6052728. DOI: 10.1007/s12291-017-0685-y.